8,275 reports of this reaction
1.3% of all CETIRIZINE HYDROCHLORIDE reports
#18 most reported adverse reaction
PEMPHIGUS is the #18 most commonly reported adverse reaction for CETIRIZINE HYDROCHLORIDE, manufactured by Kenvue Brands LLC. There are 8,275 FDA adverse event reports linking CETIRIZINE HYDROCHLORIDE to PEMPHIGUS. This represents approximately 1.3% of all 615,076 adverse event reports for this drug.
Patients taking CETIRIZINE HYDROCHLORIDE who experience pemphigus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PEMPHIGUS is a less commonly reported adverse event for CETIRIZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to pemphigus, the following adverse reactions have been reported for CETIRIZINE HYDROCHLORIDE:
The following drugs have also been linked to pemphigus in FDA adverse event reports:
PEMPHIGUS has been reported as an adverse event in 8,275 FDA reports for CETIRIZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PEMPHIGUS accounts for approximately 1.3% of all adverse event reports for CETIRIZINE HYDROCHLORIDE, making it a notable side effect.
If you experience pemphigus while taking CETIRIZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.